HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Defects in the Proteome and Metabolome in Human Hypertrophic Cardiomyopathy.

AbstractBACKGROUND:
Defects in energetics are thought to be central to the pathophysiology of hypertrophic cardiomyopathy (HCM); yet, the determinants of ATP availability are not known. The purpose of this study is to ascertain the nature and extent of metabolic reprogramming in human HCM, and its potential impact on contractile function.
METHODS:
We conducted proteomic and targeted, quantitative metabolomic analyses on heart tissue from patients with HCM and from nonfailing control human hearts.
RESULTS:
In the proteomic analysis, the greatest differences observed in HCM samples compared with controls were increased abundances of extracellular matrix and intermediate filament proteins and decreased abundances of muscle creatine kinase and mitochondrial proteins involved in fatty acid oxidation. These differences in protein abundance were coupled with marked reductions in acyl carnitines, byproducts of fatty acid oxidation, in HCM samples. Conversely, the ketone body 3-hydroxybutyrate, branched chain amino acids, and their breakdown products, were all significantly increased in HCM hearts. ATP content, phosphocreatine, nicotinamide adenine dinucleotide and its phosphate derivatives, NADP and NADPH, and acetyl CoA were also severely reduced in HCM compared with control hearts. Functional assays performed on human skinned myocardial fibers demonstrated that the magnitude of observed reduction in ATP content in the HCM samples would be expected to decrease the rate of cross-bridge detachment. Moreover, left atrial size, an indicator of diastolic compliance, was inversely correlated with ATP content in hearts from patients with HCM.
CONCLUSIONS:
HCM hearts display profound deficits in nucleotide availability with markedly reduced capacity for fatty acid oxidation and increases in ketone bodies and branched chain amino acids. These results have important therapeutic implications for the future design of metabolic modulators to treat HCM.
AuthorsMichael J Previs, Thomas S O'Leary, Michael P Morley, Bradley M Palmer, Martin LeWinter, Jaime M Yob, Francis D Pagani, Christopher Petucci, Min-Soo Kim, Kenneth B Margulies, Zoltan Arany, Daniel P Kelly, Sharlene M Day
JournalCirculation. Heart failure (Circ Heart Fail) Vol. 15 Issue 6 Pg. e009521 (06 2022) ISSN: 1941-3297 [Electronic] United States
PMID35543134 (Publication Type: Journal Article, Research Support, U.S. Gov't, Non-P.H.S., Research Support, N.I.H., Extramural)
Chemical References
  • Amino Acids, Branched-Chain
  • Fatty Acids
  • Proteome
  • Adenosine Triphosphate
Topics
  • Adenosine Triphosphate (metabolism)
  • Amino Acids, Branched-Chain (metabolism)
  • Cardiomyopathy, Hypertrophic
  • Fatty Acids (metabolism)
  • Heart Failure (metabolism)
  • Humans
  • Metabolome
  • Myocytes, Cardiac (metabolism)
  • Proteome
  • Proteomics

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: